Abstract

Purpose: To develop a prospective non-muscle-invasive bladder cancer (NMIBC) data registry by generating NMIBC-specific electronic case report forms (eCRFs) in our institution's electronic patient file system, and to report on the development and implementation of a prospective multicentric registry.Methods: Templates for data collection, including clinical outcome parameters and quality indicators, were developed in InfoPath™ as an eCRF and were incorporated in our hospital's electronic patient file system. Quality parameters for managing NMIBC patients that were identified by comprehensive literature review were included in the eCRFs. Three separate eCRFs were developed for the management of NMIBC patients: surgery report, bladder instillation form, and multidisciplinary team form.Results: In August 2013, we started a Flemish prospective clinical and pathological data registry for all patients undergoing transurethral resection of bladder tumor (TURBT) for NMIBC in four participating hospitals, three of which continued using this to date. Three more hospitals started enrolling in 2017, 2018, and 2019, respectively. Written reports of the registered clinical actions are automatically generated within the electronic medical file. When urologists complete these eCRFs, an automated ready-to-send letter to the general practitioner is generated. Up till May 2019, 2,756 TURBTs in 2,419 patients are included in the dataset. Currently, we are recruiting over 600 TURBTs every year.Conclusions: Easy-to-use eCRFs were developed and included in the electronic patient file system. This registration tool was implemented in 7 hospitals, 6 of which are still using it today. The register harvests important clinical data, while performing routine clinical practice. The data will be used to analyze real-life data of NMIBC patients, to challenge the existing guidelines, to create novel risk stratification tools, and to develop, monitor and validate quality parameters for NMIBC management.

Highlights

  • Bladder cancer (BC) is a major health problem, as it is the ninth most commonly diagnosed form of cancer, and accounts for 3% of all cancer-related deaths in Europe [1]

  • As timely updating of the currently used and above-mentioned datasets is impossible, a prospective dataset needs to be developed. Keeping these unmet needs and deficiencies of the former risk stratifications in mind, we developed a prospective non–muscle-invasive bladder cancer (NMIBC) data registry by generating NMIBC-specific electronic case report forms

  • We report on the development of these electronic case report forms (eCRFs) and their implementation in a prospective multicentric registry

Read more

Summary

Introduction

Bladder cancer (BC) is a major health problem, as it is the ninth most commonly diagnosed form of cancer, and accounts for 3% of all cancer-related deaths in Europe [1]. The large majority of detected lesions (±75%) are classified as non–muscle-invasive bladder cancer (NMIBC). These superficial lesions are defined as Ta, T1, or carcinoma in situ (CIS). The primary treatment for NMIBC is the removal of all cancerous tissue from the bladder, called transurethral resection of bladder tumor (TURBT), which is used both as a diagnostic and therapeutic tool. Accurate and early diagnosis of NMIBC is essential to offer the patients the most appropriate treatment and the highest cure rate. NMIBC patients are scheduled to undergo frequent monitoring, currently based on cystoscopy and cytology, which makes BC one of the costliest of all cancers to manage [3, 4]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.